BNP Paribas Financial Markets Has $16.63 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

BNP Paribas Financial Markets lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 26.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 154,037 shares of the medical equipment provider's stock after selling 54,250 shares during the period. BNP Paribas Financial Markets owned 0.08% of Zimmer Biomet worth $16,628,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZBH. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the third quarter worth approximately $31,000. Family Firm Inc. acquired a new position in Zimmer Biomet during the second quarter valued at approximately $33,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Zimmer Biomet in the second quarter worth $43,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ZBH shares. Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. Truist Financial lifted their price objective on Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a research note on Friday, November 1st. Royal Bank of Canada boosted their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday, November 4th. UBS Group cut their price objective on Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating for the company in a research report on Thursday, August 8th. Finally, Canaccord Genuity Group cut their price target on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, September 10th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $123.22.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded up $0.08 during mid-day trading on Friday, hitting $112.10. 504,058 shares of the company were exchanged, compared to its average volume of 1,527,881. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average of $107.29 and a 200 day moving average of $109.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The company has a market capitalization of $22.32 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the company posted $1.65 earnings per share. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.